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Burkholderia cepacia complex organisms are important transmissible pathogens found in cystic fibrosis (CF) patients. In recent
years, the rates of cross-infection of epidemic strains have declined due to effective infection control efforts. However, cases of
sporadic B. cepacia complex infection continue to occur in some centers. The acquisition pathways and clinical outcomes of spo-
radic B. cepacia complex infection are unclear. We sought to determine the patient clinical characteristics, outcomes, incidence,
and genotypic relatedness for all cases of B. cepacia complex infection at two CF centers. We also sought to study the external
conditions that influence the acquisition of infection. From 2001 to 2011, 67 individual organisms were cultured from the respi-
ratory samples of 64 patients. Sixty-five percent of the patients were adults, in whom chronic infections were more common
(68%) (P 0.006). The incidence of B. cepacia complex infection increased by a mean of 12% (95% confidence interval [CI], 3 to
23%) per year. The rates of transplantation and death were similar in the incident cases who developed chronic infection com-
pared to those in patients with chronic Pseudomonas aeruginosa infection. Multilocus sequence typing revealed 50 individual
strains from 65 isolates. Overall, 85% of the patients were infected with unique strains, suggesting sporadic acquisition of infec-
tion. The yearly incidence of nonepidemic B. cepacia complex infection was positively correlated with the amount of rainfall in
the two sites examined: subtropical Brisbane (r 0.65, P 0.031) and tropical Townsville (r 0.82, P 0.002). This study dem-
onstrates that despite strict cohort segregation, new cases of unrelated B. cepacia complex infection continue to occur. These
data also support an environmental origin of infection and suggest that climate conditions may be associated with the acquisi-
tion of B. cepacia complex infections.
Burkholderia cepacia complex organisms are important respira-tory pathogens in persons with cystic fibrosis (CF). Infection
with B. cepacia complex organisms can result in increasedmortal-
ity and morbidity, including “cepacia syndrome,” and it has been
associated with person-to-person transmission and poor out-
comes following lung transplantation (1–5). Currently, the B. ce-
pacia complex comprises 17 distinct species (6, 7). The recogni-
tion of transmissible strains led to improved microbiological
screening protocols and the implementation of strict infection
control policies that resulted in lower person-to-person transmis-
sion rates (8–10). While these policies have been successful in
reducing cross-infections of epidemic strains, sporadic cases of B.
cepacia complex infections continue to occur (11–14).
The routes of acquisition of sporadic B. cepacia complex infec-
tions in CF are not well understood, yet it is clear that environ-
mental and clinical strains are closely related, with indistinguish-
able genotypes isolated from ecological niches and patients
(15–17). Consequently, the environment is now recognized as a
likely source of acquisition for sporadic strains, but relatively little
is known about other factors that influence acquisition (14). Re-
cent studies of Burkholderia pseudomallei, the etiological agent of
melioidosis, have demonstrated that both the type of natural res-
ervoir (e.g., soil) and other influencing factors (e.g., increased
rainfall) play roles in acquisition (18, 19).
Our primary aim was to establish the incidence, prevalence,
epidemiology, and outcomes of B. cepacia complex infection
among persons with CF in Queensland, Australia, during an 11-
year period. We also sought to assess the patient clinical charac-
teristics at the time of infection. A secondary aim was to assess the
impact of weather conditions on incidence rates of new cases of B.
cepacia complex infection.
MATERIALS AND METHODS
Patients, data, and isolate collection. All cases of B. cepacia complex, B.
pseudomallei, and Burkholderia gladioli infections detected in CF patients
attending The Prince Charles Hospital Adult CF Center and the Royal
Children’s Hospital Pediatric CF Center, Queensland, Australia, between
January 2001 and December 2011 were included in the study. These hos-
pitals are the major adult and pediatric CF centers for Queensland, pro-
viding care for almost 600 of the 758 CF patients in Queensland (20). The
patient clinical details, including age, sex, copathogens, forced expiratory
volume in 1 s (FEV1), forced vital capacity (FVC), and body mass index
(BMI) at the time of first infection, were recorded in patients who ac-
quired B. cepacia complex infections during the study period. Age-ad-
justed pulmonary function prediction equations were used (21, 22), and
BMI z-scores (for children) were calculated using United States National
Center for Health Statistics and Centers for Disease Control normalized
growth reference values in children. Chronic B. cepacia complex infec-
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tions were defined as those with 50% of samples collected over the
following 12 months being culture positive, using a modification of the
Leeds criteria (23). Transient infections were defined as those with50%
of samples collected over the following 12 months being culture positive
and when no infection was identified during the preceding 12 months.
The numbers of deaths and lung transplants following the acquisition of
B. cepacia complex were recorded.
All isolates presumed to be B. cepacia complex by phenotype that were
cultured from the respiratory tract of CF patients (sputum, bronchoal-
veolar lavage [BAL] fluid, and oropharyngeal swabs) were included. Cul-
ture methods were standardized between the study sites, and there were
no changes in the culture protocols throughout the study period. The
isolates were initially referred to a reference laboratory for phenotypic
profiling and confirmatory B. cepacia complex-specific recA PCR as pre-
viously described (13, 24), and the confirmed isolates were forwarded to a
research laboratory for species identification and genotyping using mul-
tilocus sequence typing (MLST). Molecular analyses of recurrent isolates
were performedwhen the clinical laboratory observed changes in the phe-
notypic characteristics compared to earlier isolates from the same patient.
Species identification and genotyping. TheMLST reagents, primers,
and reaction conditions were identical to those described on theB. cepacia
complex PubMLST website (see http://pubmlst.org/bcc/) (25). Thermal
cyclingwas performed in aBio-RadMyCycler personal thermal cycler and
cycle sequencing was undertaken by the Australian Genome Research
Facility using the BigDye Terminator version 3.1 cycle sequencing kit and
anABI 3730xl genetic analyzer (Applied Biosystems, Inc., Foster City, CA,
USA). Sequence verification and editing were performed using Sequence
Scanner version 1.0 (Applied Biosystems, Inc.) and Vector NTI Advance
11.0 (Invitrogen Australia Pty, Ltd.) software.
Species identification by recA gene sequence analysis and sequence
type (ST) assignment was performed using the B. cepacia complex
PubMLST database (see http://pubmlst.org/bcc/) (25). The extended
MLST protocol was utilized for samples showing low-quality PCR ampli-
cons using the standardMLSTprimer set (26). Species-level identification
of isolates showing novel recA sequences was undertaken by constructing
a phylogenetic tree of the concatenated nucleotide sequences from the
seven MLST loci of established B. cepacia complex species (neighbor-
joining method with distances calculated using the Juke and Cantor algo-
rithm) using the MEGA software version 5.2, as previously described (6).
Isolates presumed to beB. pseudomallei andB. gladioliwere confirmed
using previously described 16S rRNA gene PCR assays (27, 28). Genotyp-
ing was performed on confirmed isolates using repetitive extragenic pal-
indromic sequence-based PCR (rep-PCR) analysis (13).
Epidemiological analysis. Details of the person-to-person contact
history for each infection, including overlapping same-center care (i.e.,
inpatient and outpatient care) and known social contacts, were provided
by the CF center directors and nurse specialists.
Statistical analysis. Continuous variables were summarized as the
mean and standard deviation (SD) and categorical variables as the fre-
quency (in percentage). Patients with B. cepacia complex, defined as those
who had culture-confirmed B. cepacia complex infection on at least one
occasion, were compared to patients without B. cepacia complex infec-
tions using Student’s t test. Using Fisher’s exact test, the rates of mortality
and transplantation were compared between adult patients who acquired
a chronic B. cepacia complex infection and between patients with chronic
P. aeruginosa infection, irrespective of the presence of copathogens. Using
linear regression, we investigated the association between study year and
disease prevalence for the whole cohort and the two CF centers individu-
ally. The association between the study year and disease incidence was
investigated using Poisson regression with robust standard errors. Model
assumptions were tested with the deviance goodness-of-fit statistic. A P
value of0.05 was used to define statistical significance.
Meteorological analysis. The association between the incidence of
infection with nonepidemic B. cepacia complex strains and meteorologi-
cal factorswas investigated by both spatial and time series analyses. For the
spatial analysis, patients with CF were divided into those residing north
and south of the Tropic of Capricorn (23.5° south of the equator), and the
incidence rates were compared in these patients over the 11 years of the
study. To calculate the incidence rates, we divided the total number of
incident cases by the total number patients at risk each year. For the time
series analysis, we selected the two cities with the largest numbers of pa-
tients with CF: subtropical Brisbane and tropical Townsville. Yearly inci-
dence rates (the number of incident cases that year divided by the number
of patients at risk that year) were compared with yearly rainfall amount,
mean dew point at 9 a.m., and the mean temperature at 9 a.m., using
Spearman’s correlation. For both analyses, patients at risk were defined as
those patients having had two or more cultures that year. Correlations
were assessed on a yearly time scale because of the difficulty in determin-
ing the exact date of B. cepacia complex acquisition. The meteorological
data used in the analyses were taken frommeteorological records from the
Brisbane and Townsville airports, available from the Australian Govern-
ment Bureau of Meteorology (see http://www.bom.gov.au/).
Ethics statement. The Prince Charles Hospital Ethics Committee ap-
proved the study (HREC/13/QPCH/51), and patient consent was not re-
quired for this analysis.
RESULTS
Patient characteristics. At least one B. cepacia complex, B. pseu-
domallei, or B. gladioli organism was isolated from the respiratory
tracts of 73 patients over the study period (54 adults and 19 chil-
dren). Sixty-five percent of patients withB. cepacia complex infec-
tion were 18 years of age, 59.4% were male, and 51.2% were
homozygous for the pF508del mutation. Ninety-four percent of
the B. cepacia complex isolates were cultured from expectorated
sputum samples, with the remaining samples comprising twoBAL
fluid and one oropharyngeal swab in three pediatric patients and
one isolate referred from a private laboratory. For the adult pa-
tients, the rate of sample collection in the B. cepacia complex co-
hort (5.1 mean samples/patient/year) was similar to that for the
whole population (4.8 mean samples/patients/year). For all pa-
tients who acquired B. cepacia complex infection (including those
in whom the infection was transient), 43% of the respiratory sam-
ples were positive after the initial detection, whereas 85% were
positive for those who developed a chronic infection.
Clinical and microbiological characteristics of incident
cases. Since 2001, there have been 64 patients withB. cepacia com-
plex infection, including 48 (75%) who acquired B. cepacia com-
plex infection during the study period. The clinical and microbi-
ological characteristics of the new (incidence cases) group are
presented in Table 1. The rates of codetectionwith P. aeruginosa at
the adult and pediatric CF centers were 87% and 53%, respec-
tively. Chronic infection was more common in adults (19/28
[68%]) than in children (4/17 [24%]) (P  0.006). Those pa-
tients with chronic B. cepacia complex infection had poorer
lung function at the time of first infection detection (mean
[SD] FEV1% predicted, 49.1 [20.0]; FVC% predicted, 70.0
[19.0]) compared with patients with transient infection
(FEV1% predicted, 77.5 [19.8] [P  0.001]; FVC% predicted,
88.7 [15.0] [P  0.003]).
Of the adult patients who acquired a B. cepacia complex infec-
tion during the study (n 30), 23 developed a chronic infection.
Five of these patients died (including one following lung trans-
plantation) and three survived following transplantation. Com-
pared with adults with chronic P. aeruginosa infection, the rates of
transplantation, death, and death following transplantation were
similar (P  0.75, 0.09, and 0.57, respectively). Of the children,
Ramsay et al.
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two patients died and one survived following lung transplanta-
tion.
Outcomes of Burkholderia cenocepacia Australian epidemic
strain (ST-39) infections. During the 11-year study, eight of the
nine cases (including five patients who had the Australian epi-
demic strain at the start of the study period) infected with the
Australian epidemic strain died (all were adults with chronic in-
fections). In contrast, only six of the other 24 adult patients with
chronic B. cepacia complex infection (i.e., those who did not have
Australian epidemic strain infection) died (P 0.002).
Mixed Burkholderia spp., B. pseudomallei, and B. gladioli
infections. While the majority of patients (95%) were infected
with oneB. cepacia complex species, there were three patients who
acquired a second B. cepacia complex species during the study
period. In two cases, these infections occurred simultaneously,
while in the third patient, the isolations were separated by 9 years.
In addition to those patients with only B. cepacia complex infec-
tion, 13 patients each had B. pseudomallei and/or B. gladioli infec-
tion. These included four patients who were infected with one B.
cepacia complex species and either B. pseudomallei (n  2) or B.
gladioli (n 2) during the study. Another nine patients had either
B. pseudomallei (n 4),B. gladioli (n 4) or both (n 1)without
B. cepacia complex infection. All cases of mixed Burkholderia spp.
infection were observed in adults.
Prevalence and incidence. The prevalence and incidence of B.
cepacia complex infections between January 2001 and December
2011 are presented in Table 2. The prevalence was stable during
the study period for all patients. The mean increase in cases each
study year was 0.20 (95% confidence interval [CI],0.03 to 0.43)
(P  0.09); for adults, the mean increase was 0.17 (95% CI,
0.46 to 0.11) (P 0.20), and for children, it was 0.27 (95% CI,
0.04 to 0.79;P 0.07). The incidence increased during the study
period by an average of 12% per year (incidence rate ratio [IRR],
1.12 [95%CI, 1.03 to 1.23]) (P 0.009). The increase in incidence
was significant in adults (IRR, 1.18 [95% CI, 1.08 to 1.29]) (P 
0.001) but not children (IRR, 1.05 [95% CI, 0.91 to 1.21]) (P 
0.54).
Species identification and diversity. Sixty-seven B. cepacia
complex organisms were cultured from the 64 patients, of which
65 isolates were available for recA gene sequence analysis and
MLST. Sequence analysis of the recA gene for these isolates re-
vealed 36 distinct alleles. The species diversity of the Burkholderia
species isolates are presented in Table 3. Fifty-four isolates were
identified to the species level using the B. cepacia complex Pub-
MLST database, and eight of the 11 isolates containing novel recA
gene sequences were reliably identified by phylogenetic sequence
analysis of established B. cepacia complex species. The most fre-
TABLE 1 Clinical and microbiological characteristics of the study
patients who acquired Burkholderia cepacia complex infections between
2001 and 2011
Patient characteristicsa
Results for patients at the CF
center for:
Adults
(n 30)
Pediatrics
(n 18)b
Age (mean [SD]) (yr) 26.6 (9.1) 8.9 (4.8)
Sex (no. [%] males) 23 (77) 8 (44)
CFTR genotype (no. [%])
p.delF508 homozygous 11 (37) 9 (50)
Chronic infection (no. [%])c 19 (68)d 4 (24)
Died (no. [%]) 5 (17) 2 (12)e
Lung transplantation (no. [%]) 4 (13) 1 (6)
Died after transplant 1 (3) 0 (0)
BMI (mean [SD]) 21.5 (5.7) 0.46 (0.11)
FEV1 (mean [SD]) (% predicted) 52.4 (22.7) 81.5 (17.2)
f
FVC (mean [SD]) (% predicted) 71.7 (21.9) 89.6 (15.5)f
Copathogens (no. [%])
Pseudomonas aeruginosa 26 (87) 9 (53)
MSSA 19 (63) 6 (35)
Aspergillus spp. 13 (43) 4 (23)
a CFTR, cystic fibrosis transmembrane conductance regulator; BMI, body mass index
(values are BMI z-scores for patients age18 years); FEV1, forced expiratory volume in
1 s; FVC, forced vital capacity; MSSA, methicillin-susceptible Staphylococcus aureus.
b Data available for only 17 pediatric patients.
c Chronic infection was defined by the Leeds criteria (23).
d Data available for only 28 patients due to limited duration of follow-up.
e One of the children died at age 20 years in adult care from acute myeloid leukemia.
f Lung function data not included for 5 children due to age of acquisition.
TABLE 2 Annual prevalence and incidence of infections with nonepidemic strains of B. cepacia complex
Yr
Infection data by location
Adult CF centera Pediatric CF centerb Combined
No. of
patients
Prevalence
(%)
Incidence
(%)
No. of
patients
Prevalence
(%)
Incidence
(%)
No. of
patients
Prevalence
(%)
Incidence
(%)
2001 152 10.5 0.7 241 0.4 0.4 393 4.3 0.5
2002 176 9.7 1.1 242 0.4 0.0 418 4.3 0.5
2003 194 8.2 0.5 246 0.4 0.0 440 3.9 0.2
2004 217 7.4 0.5 280 1.1 0.7 497 3.8 0.6
2005 216 6.9 0.5 278 1.1 0.7 494 3.6 0.6
2006 215 4.7 0.5 284 2.5 2.1 499 3.4 1.4
2007 235 5.5 1.3 303 1.3 0.3 538 3.2 0.7
2008 242 6.2 2.1 323 1.5 0.6 565 3.5 1.2
2009 248 6.0 2.0 331 1.8 0.6 579 3.6 1.2
2010 265 5.3 1.9 328 1.5 0.6 593 3.2 1.2
2011 272 5.9 1.1 318 0.6 0.0 590 3.1 0.5
a The incidence rate ratio for B. cepacia complex cases at the adult CF center was 1.18 (95% CI, 1.08 to 1.29) (P 0.001).
b The incidence rate ratio for B. cepacia complex cases at the pediatric CF center was 1.05 (95% CI, 0.91 to 1.21) (P 0.54).
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quently encountered B. cepacia complex species included B. ceno-
cepacia, Burkholderia multivorans, and B. cepacia.
Multilocus sequence typing and rep-PCR genotyping. All of
the 65 B. cepacia complex isolates were typeable by MLST, reveal-
ing 50 individual STs (see Dataset S1 in the supplemental mate-
rial). Seventy-two percent (n 36) of the STs were novel. Overall,
therewas a high degree of genotype diversity, with 85%(n 40) of
patients infected with unique STs, while only seven STs repre-
sented genotypes found in clusters of two or more patients (see
Dataset S1 in the supplemental material). Nine adults, including
four incident cases (during the period 2001 to 2004), were infected
with theB. cenocepaciaAustralian epidemic strain (ST-39) (13).B.
cepacia strain ST-675 was common to three patients, and STs 181,
434, 632, 673, and 703 were each detected in clusters of two pa-
tients. rep-PCR analysis of the 14 B. pseudomallei and B. gladioli
isolates revealed unique genotypes in all instances (data not
shown).
Epidemiological analyses.Of the nine adults with the B. ceno-
cepacia Australian epidemic strain (ST-39), four acquired the in-
fection during the study period and had documented having close
social contact outside the hospital setting. Since 2004, there have
been no new cases of this strain. In all other instances of B. cepacia
(ST-675), B. multivorans (ST-181), and B. cenocepacia (STs 434,
632, 673, and 703) shared strain infections, there was no evidence
of personal contact between patients either at the CF center or
outside the hospital.
Meteorological analyses. The rate of nonepidemic B. cepacia
complex infection was significantly higher in patients with CF
residing north of the Tropic of Capricorn than in those residing
south of the Tropic of Capricorn (IRR, 2.61; 95%CI, 1.03 to 6.11).
In the time series analysis, the amount of rainfall was positively
correlated with the yearly incidence of infection in both Brisbane
and Townsville (Table 4).
DISCUSSION
This study shows that accurate identification of B. cepacia com-
plex organisms coupled with the implementation of strict patient
segregation (27, 29) have reduced the spread of epidemic strains.
In contrast to earlier reports (13, 30), only four instances of likely
cross-infection resulting in the acquisition of the B. cenocepacia
Australian epidemic strain were identified, and there was evidence
of close personal contact outside the hospital between these pa-
tients. However, our study has also confirmed that sporadic cases
of B. cepacia complex infection continue to occur and new cases
are occurring more frequently. These cases also demonstrated ge-
notypic diversity and novel STs. Together, these data suggest that
the environment is the likely source of acquisition.
Several studies have provided evidence of environmental iso-
lates recovered from various natural, agricultural, pharmaceuti-
cal, and industrial sources that are indistinguishable from those
isolated from persons with CF (14, 15, 17). The changes in species
diversity in several CF centers following the introduction of strict
infection controls may also be attributable to the acquisition of
environmental B. cepacia complex infection (11, 12). Notably, we
also predominantly encountered nonepidemic B. cenocepacia, B.
multivorans, and B. cepacia isolates, along with a broad range of
recently described species, including Burkholderia arboris, Burk-
holderia contaminans, Burkholderia diffusa, and Burkholderia lat-
ens (6, 7).
In our earlier work (13), we speculated that increased rates of
B. cepacia infections in CF patients living in subtropical regions of
Australia may be attributable to particular environmental niches
for specific Burkholderia species. Alternatively, differences in cli-
matic or other environmental conditions, as we have observed
with P. aeruginosa (31, 32), might play a role in variations in the
prevalences of environmental opportunistic pathogens in CF.
During periods of monsoonal rainfall in tropical areas, the inci-
dence of B. pseudomallei infections is known to increase signifi-
cantly (19).We report that the yearly incidence of nonepidemicB.
cepacia complex infection was significantly correlated with higher
rainfall amount in the two sites studied (subtropical Brisbane and
tropical Townsville). In addition, we found that the incidence rate
over the 11 years of the study was higher in patients from tropical
regions north of the Tropic of Capricorn. This suggests that the
acquisition of B. cepacia complex infection may be linked with
increased rainfall. Environmental surveys to determine bacterial
persistence and the load over time and during different weather
conditions may further explain the changes in infection rates over
time.
Earlier studies demonstrated that B. cepacia complex infection
is associated with increased morbidity and mortality for patients
with CF (2, 8). However, most of these studies have focused on
clinical outcomes in patients with epidemic and virulent geno-
types, such as the B. cenocepacia ET-12 strain (33). Our results
show that patients with chronic infections had lower lung func-
TABLE 3 Burkholderia species diversity among the study patients
Burkholderia sp. and/or recA
lineage
No. (%) of isolates in:
Totala
Adult CF
center
Pediatric CF
center
Burkholderia cepacia complex 65 (100.0) 48 (73.8) 17 (26.2)
B. cenocepacia recA lineage B 17 (26.2) 11 (22.9) 6 (35.3)
B. multivorans 17 (26.2) 13 (27.1) 4 (23.5)
B. cenocepacia recA lineage A 11 (16.9) 10 (20.8) 1 (5.9)
B. cepacia 8 (12.3) 5 (10.4) 3 (17.6)
B. vietnamiensis 3 (4.6) 3 (6.3)
B. ambifaria 1 (1.5) 1 (2.1)
B. arboris 1 (1.5) 1 (2.1)
B. contaminans 1 (1.5) 1 (5.9)
B. diffusa 1 (1.5) 1 (2.1)
B. latens 1 (1.5) 1 (5.9)
B. pyrrocinia 1 (1.5) 1 (5.9)
Indeterminant 3 (4.6) 3 (6.3)
B. gladioli 7 (100.0) 6 (85.7) 1 (14.3)
B. pseudomallei 7 (100.0) 7 (100.0)
a Eight patients were infected with two different Burkholderia species during the study
period.
TABLE 4 Correlation of yearly incidence rates of nonepidemic strains
of B. cepacia complex infection in Brisbane and Townsville with local
weather conditions, 2001 to 2011
Meteorological
variable
Values for:
Brisbane Townsville
Correlation P Correlation P
Rainfall 0.65 0.031 0.82 0.002
Dew point 0.47 0.147 0.25 0.453
Temperature 0.04 0.911 0.51 0.113
Ramsay et al.
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tion than patients with transient infections. Furthermore, adult
patients had lower lung function and were more likely to have
chronic B. cepacia complex infection and other airway CF patho-
gens identified than children. When patients with chronic B. ce-
pacia complex were compared to patients with chronic P. aerugi-
nosa, irrespective of other copathogens, we observed no increase
in mortality or requirement for lung transplantation. We did,
however, find increased mortality in patients attending the adult
center with the B. cenocepacia Australian epidemic strain (ST-39)
compared to those with nonepidemic B. cepacia complex infec-
tion.
Other studies have also suggested that the clinical outcomes for
patients infected with B. cepacia complex are species dependent
and that the host-pathogen interaction is also likely to play a role
in virulence and clinical impacts (14, 33, 34). Jones and colleagues
(33) reported excess mortality and accelerated clinical decline in
patients with the ET-12 strain, whereas our study, which was
dominated by sporadic B. cepacia complex infection, did not find
increased rates of mortality or the need for lung transplantation.
We have not performed further clinical outcome analyses at this
stage, aswe had a small number of patientswhodeveloped chronic
infection; however, this will be important to perform in the future
(i.e., with larger numbers of patients), as nonepidemic B. cepacia
complex infection may not have the same impact on clinical out-
comes as epidemic strains, which are less prevalent in most CF
centers in the current era. It is also known that person-to-person
transmission is strain dependent and that some strains are more
adapted to causing human infection than others (12). While it
appears that the major epidemic strains belonging to B. cenocepa-
cia (including ET-12, PHDC, and ST-39) are more transmissible
than other strains, outbreaks of other species have the potential to
occur (12, 14).
Several studies have demonstrated that themajority of patients
who acquire B. cepacia complex infection develop chronic infec-
tions (35–37). A Portuguese study reported that pediatric patients
with CF had more frequent chronic infections than transient in-
fections (35). Our finding differed, and we report here that infec-
tions in younger patients were more likely to be transient, and
when transient, they occurred in patients with better lung func-
tion. An eradication program for pediatric patients with newly
acquired B. cepacia complex infection may be a significant factor
for this difference, and there is some support in the literature for
this idea (37). However, spontaneous clearancemay also occur, as
we have demonstrated in patients with methicillin-resistant
Staphylococcus aureus infection (38).
When indistinguishable genotypes of bacterial pathogens are
isolated from patients with CF, it is suggested that health care-
associated transmission or exposure to common environmental
strains was the route of acquisition. Our recentMLST studies of P.
aeruginosa in Australia confirm the presence of numerous shared
strains, many of which are widespread in other local and interna-
tional ecological settings, thus increasing the potential for infec-
tion in the susceptible host, e.g., the CF lung (31, 39). In the cur-
rent study, we also observed several small clusters of patients with
indistinguishable B. cepacia, B. multivorans, and B. cenocepacia
STs, which were not associated with person-to-person transmis-
sion. Furthermore, four of the strains detected during this study
were recently encountered among nonepidemic clinical isolates
fromNewZealand, including the shared strain ST-181, which was
isolated from two unrelated patients with CF (40).
Our data show that B. gladioli accounted for10% of all Burk-
holderia species infections across the study period. In contrast,
data fromNorth America indicate that B. gladioli is the thirdmost
common Burkholderia species encountered in patients with CF
(41). All but one patient with B. gladioli lived in subtropical areas
at the time of acquisition, while, consistent with our earlier obser-
vations,most patients withB. pseudomallei infection lived in trop-
ical regions (28). Genotypic analysis of these species confirmed
unique genotypes among all patients, suggesting independent ac-
quisition of infection.
In conclusion, despite strict cohort segregation and infection
control policies, new cases of B. cepacia complex infection con-
tinue to occur. These cases in recent years have been dominated by
unique strains and are likely to be acquired from the environment.
We have demonstrated several lines of evidence to support this,
including (i) a lack of epidemiological linkage between patients
with the same strain, (ii) the potential linkage with changes in
rainfall, and (iii) a high number of nonepidemic, unrelated, and
novel strains.
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